 With the anticipation of a 2Q program update, Verastem Oncology NASDAQ: VSTM announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer LGSOC continue evaluation in both monotherapy and combination regimens. . 